Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cendakimab - Receptos

Drug Profile

Cendakimab - Receptos

Alternative Names: ABT-308; RPC-4046

Latest Information Update: 05 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Receptos
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis
  • Discontinued Allergic asthma

Most Recent Events

  • 05 Aug 2019 INN list 120_A: Added AN and modified profile accordingly, added CAS number in chemical info and sent request to modify THES
  • 22 Feb 2019 Efficacy and safety data from the open-label extension phase of the phase II HEROES study presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2019)
  • 24 Oct 2018 RPC 4046 is still in phase II trials for Eosinophilic esophagitis (Celgene pipeline, October 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top